ARTIS Ventures

www.av.co

VCMatch tracks ARTIS Ventures as an investor focused on AI/ML, Biotech, and Digital Health companies, Pre-Seed and Seed rounds, and United States, San Francisco, Ca, and Global / International markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A, Series B

Focus Areas

AI/ML, Biotech, Digital Health

Geography

United States, San Francisco, CA, and Global / international

Investment Thesis

ARTIS positions itself at the intersection of technology and biology (which it calls “TechBio”) and emphasizes an engineering-first, data-driven approach to life sciences and health. The firm prioritizes companies that apply computation, AI, and strong datasets to reduce cost and time in drug development and to build scalable medical technologies that “solve problems affecting everyday people from across the globe.” ARTIS also frames its mandate around a broadened concept of national and public health security — calling this horizon “Global Resilience” — and seeks to accelerate deployment of mission‑critical technologies into public health, critical infrastructure, digital security, and crisis response.

Is ARTIS Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

ARTIS Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in AI/ML, Biotech, Digital Health, and Medtech, especially across United States, San Francisco, CA, and Global / international.

Focus statement

ARTIS focuses on “frontier: technologies that strengthen health and security,” specifically investing in “data-driven life sciences companies” and TechBio+Health startups that combine computer science and cellular biology to enable cures, personalized therapeutics, and faster drug discovery.

Value Add

Coined and centers investment around the term and thesis “TechBio” / “Tech Bio+Health”, explicitly combining computer science with cellular biology.
Explicit focus on “Global Resilience” — investing not just in health/therapeutics but in technologies that protect public health, critical infrastructure and national security.
Engineering-first thesis: favors scalable, engineering- and AI-backed platforms and strong datasets that increase optionality and revenue streams (e.g., “Investing in companies with a Tech Bio+Health thesis ensures a plethora of indications from a singular biologically engineered approach”).
Ecosystem-driven model: leverages a global network (Healthcare Alliance, Pioneers Network, Fellows Program) to provide technical, regulatory and commercial support to portfolio companies.
Domain depth on team and network: partners and Fellows with deep scientific, clinical and regulatory experience (multiple MD/PhDs, former pharma execs, and regulatory veterans) and public recognition (Forbes Midas List, CB Insights Top 100 VCs).
Explicit go-to-market & government pathway: calls out closing the industry-government divide and delivering “mission-critical technologies into the hands of those securing tomorrow, today.”